Cargando…
The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients
BACKGROUND: Growth hormone deficiency (GHD) has been implicated in increased cardiovascular and cerebrovascular disease risk seen in hypopituitarism, however the mechanism remains speculative. We hypothesise that platelet abnormalities may play a contributory role. Herein we examined platelet behavi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500895/ https://www.ncbi.nlm.nih.gov/pubmed/37705005 http://dx.doi.org/10.1186/s12902-023-01448-6 |
_version_ | 1785106012656631808 |
---|---|
author | Oglesby, Irene K Slattery, David Glynn, Nigel Gupta, Saket Duggan, Karen Cuesta, Martin Dunne, Eimear Garrahy, Aoife Toner, Siobhan Kenny, Dermot Agha, Amar |
author_facet | Oglesby, Irene K Slattery, David Glynn, Nigel Gupta, Saket Duggan, Karen Cuesta, Martin Dunne, Eimear Garrahy, Aoife Toner, Siobhan Kenny, Dermot Agha, Amar |
author_sort | Oglesby, Irene K |
collection | PubMed |
description | BACKGROUND: Growth hormone deficiency (GHD) has been implicated in increased cardiovascular and cerebrovascular disease risk seen in hypopituitarism, however the mechanism remains speculative. We hypothesise that platelet abnormalities may play a contributory role. Herein we examined platelet behaviour in GHD hypopituitary patients, pre- and post-growth hormone (GH) replacement. METHODS: This study utilizes a physiological flow-based assay to quantify platelet function in whole blood from patient cohorts under arterial shear. Thirteen GH Naïve hypopituitary adults with GHD and thirteen healthy matched controls were studied. Patients were assessed before and after GH treatment. All other pituitary replacements were optimised before the study. In addition to a full endocrine profile, whole blood was labelled and perfused over immobilised von Willibrand factor (vWF). Seven parameters of dynamic platelet-vWF interactions were recorded using digital image microscopy and analysed by customised platelet tracking software. RESULTS: We found a significantly altered profile of platelet-vWF interactions in GHD individuals compared to healthy controls. Specifically, we observed a marked increase in platelets shown to form associations such as tethering, rolling and adherence to immobilized vWF, which were reduced post GH treatment. Speed and distance platelets travelled across vWF was similar between controls and pre-therapy GHD patients, however, this was considerably increased post treatment. This may indicate reduced platelet signaling resulting in less stable adhesion of platelets post GH treatment. CONCLUSIONS: Taken together observed differences in platelet behaviour may contribute to an increased risk of thrombosis in GHD which can in part be reversed by GH therapy. |
format | Online Article Text |
id | pubmed-10500895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105008952023-09-15 The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients Oglesby, Irene K Slattery, David Glynn, Nigel Gupta, Saket Duggan, Karen Cuesta, Martin Dunne, Eimear Garrahy, Aoife Toner, Siobhan Kenny, Dermot Agha, Amar BMC Endocr Disord Research BACKGROUND: Growth hormone deficiency (GHD) has been implicated in increased cardiovascular and cerebrovascular disease risk seen in hypopituitarism, however the mechanism remains speculative. We hypothesise that platelet abnormalities may play a contributory role. Herein we examined platelet behaviour in GHD hypopituitary patients, pre- and post-growth hormone (GH) replacement. METHODS: This study utilizes a physiological flow-based assay to quantify platelet function in whole blood from patient cohorts under arterial shear. Thirteen GH Naïve hypopituitary adults with GHD and thirteen healthy matched controls were studied. Patients were assessed before and after GH treatment. All other pituitary replacements were optimised before the study. In addition to a full endocrine profile, whole blood was labelled and perfused over immobilised von Willibrand factor (vWF). Seven parameters of dynamic platelet-vWF interactions were recorded using digital image microscopy and analysed by customised platelet tracking software. RESULTS: We found a significantly altered profile of platelet-vWF interactions in GHD individuals compared to healthy controls. Specifically, we observed a marked increase in platelets shown to form associations such as tethering, rolling and adherence to immobilized vWF, which were reduced post GH treatment. Speed and distance platelets travelled across vWF was similar between controls and pre-therapy GHD patients, however, this was considerably increased post treatment. This may indicate reduced platelet signaling resulting in less stable adhesion of platelets post GH treatment. CONCLUSIONS: Taken together observed differences in platelet behaviour may contribute to an increased risk of thrombosis in GHD which can in part be reversed by GH therapy. BioMed Central 2023-09-14 /pmc/articles/PMC10500895/ /pubmed/37705005 http://dx.doi.org/10.1186/s12902-023-01448-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Oglesby, Irene K Slattery, David Glynn, Nigel Gupta, Saket Duggan, Karen Cuesta, Martin Dunne, Eimear Garrahy, Aoife Toner, Siobhan Kenny, Dermot Agha, Amar The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients |
title | The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients |
title_full | The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients |
title_fullStr | The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients |
title_full_unstemmed | The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients |
title_short | The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients |
title_sort | modulation of platelet function by growth hormone in growth hormone deficient hypopituitary patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500895/ https://www.ncbi.nlm.nih.gov/pubmed/37705005 http://dx.doi.org/10.1186/s12902-023-01448-6 |
work_keys_str_mv | AT oglesbyirenek themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT slatterydavid themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT glynnnigel themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT guptasaket themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT duggankaren themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT cuestamartin themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT dunneeimear themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT garrahyaoife themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT tonersiobhan themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT kennydermot themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT aghaamar themodulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT oglesbyirenek modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT slatterydavid modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT glynnnigel modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT guptasaket modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT duggankaren modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT cuestamartin modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT dunneeimear modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT garrahyaoife modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT tonersiobhan modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT kennydermot modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients AT aghaamar modulationofplateletfunctionbygrowthhormoneingrowthhormonedeficienthypopituitarypatients |